Northeast Pharmaceutical Group Co Ltd Capital Reinvestment Ratio
Northeast Pharmaceutical Group Co Ltd capital reinvestment ratio. Northeast Pharmaceutical Group Co Ltd (000597) has a Capital Reinvestment Ratio of 0.04x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥274.09 Million) in capital expenditures (CN¥11.48 Million). Check 000597 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Northeast Pharmaceutical Group Co Ltd (1999–2025)
Capital reinvestment ratio of Northeast Pharmaceutical Group Co Ltd from 1999 to 2025. This chart tracks Northeast Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 23 annual periods. Also explore 000597 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Northeast Pharmaceutical Group Co Ltd Capital Reinvestment Ratio by Year (1999–2025)
Northeast Pharmaceutical Group Co Ltd capital reinvestment ratio by year from 1999 to 2025. For the full cash flow conversion analysis, see 000597 cash flow metrics.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | CN¥1.11 Billion | CN¥97.78 Million | ▼ -57.9% |
| 2024 | 0.21x | CN¥758.76 Million | CN¥159.43 Million | ▼ -47.6% |
| 2023 | 0.40x | CN¥586.75 Million | CN¥235.43 Million | ▲ +82.2% |
| 2022 | 0.22x | CN¥1.11 Billion | CN¥244.13 Million | ▲ +37.2% |
| 2021 | 0.16x | CN¥746.51 Million | CN¥119.81 Million | ▼ -77.1% |
| 2020 | 0.70x | CN¥570.92 Million | CN¥400.38 Million | ▲ +7.9% |
| 2019 | 0.65x | CN¥352.60 Million | CN¥229.17 Million | ▼ -67.2% |
| 2018 | 1.98x | CN¥285.09 Million | CN¥565.74 Million | ▲ +331.1% |
| 2016 | 0.46x | CN¥384.51 Million | CN¥177.01 Million | ▼ -86.7% |
| 2015 | 3.47x | CN¥99.70 Million | CN¥346.04 Million | ▼ -69.4% |
| 2014 | 11.33x | CN¥46.99 Million | CN¥532.27 Million | ▲ +445.1% |
| 2012 | 2.08x | CN¥86.09 Million | CN¥178.90 Million | ▲ +12.2% |
| 2010 | 1.85x | CN¥255.96 Million | CN¥473.93 Million | ▲ +32.2% |
| 2009 | 1.40x | CN¥615.91 Million | CN¥862.78 Million | ▲ +176.5% |
| 2008 | 0.51x | CN¥709.03 Million | CN¥359.27 Million | ▲ +14.6% |
| 2007 | 0.44x | CN¥198.56 Million | CN¥87.78 Million | ▼ -52.5% |
| 2005 | 0.93x | CN¥111.40 Million | CN¥103.66 Million | ▲ +221.2% |
| 2004 | 0.29x | CN¥211.06 Million | CN¥61.14 Million | ▼ -23.8% |
| 2003 | 0.38x | CN¥230.08 Million | CN¥87.46 Million | ▲ +57.1% |
| 2002 | 0.24x | CN¥157.41 Million | CN¥38.07 Million | ▼ -59.1% |
| 2001 | 0.59x | CN¥78.84 Million | CN¥46.57 Million | ▲ +75.2% |
| 2000 | 0.34x | CN¥36.13 Million | CN¥12.18 Million | ▲ +95.9% |
| 1999 | 0.17x | CN¥54.62 Million | CN¥9.41 Million | — |